论文部分内容阅读
目的从文献计量学角度了解国内2001-2011年乳腺癌药物治疗的研究情况。方法以中国生物医学文献数据库为数据源,利用文献计量学方法,对国内公开发表的乳腺癌药物治疗研究文献进行分析。结果 2001-2011年我国乳腺癌药物治疗文献2 466篇,年均224篇,其中2006年篇数最多为335篇,2011年篇数最少为182篇。有2篇以上文献的药物68种,20种主要治疗乳腺癌的药物中以紫杉醇、顺铂、长春瑞滨和卡培他滨等4种药物治疗的文献最多达929篇。结论 2001-2011年我国乳腺癌药物治疗文献量基本平稳,乳腺癌药物治疗的热点为紫杉醇、顺铂等。
Objective To understand the research status of breast cancer drug therapy in China from 2001 to 2011 from the perspective of bibliometrics. Methods Based on the data from China Biomedical Literature Database and the bibliometrics method, the research literature on breast cancer drug treatment published in China was analyzed. Results A total of 2 466 articles on breast cancer drug therapy were published in 2001-2011 in China, with an annual average of 224 articles. Among them, the articles with the highest number of articles in 2006 were 335 articles, and the articles with at least 182 articles in 2011 articles. There were 68 articles of medicine with more than two articles, and up to 929 articles of literature were used to treat 20 kinds of drugs which mainly treat breast cancer, such as paclitaxel, cisplatin, vinorelbine and capecitabine. Conclusion The literature volume of breast cancer drug treatment in China from 2001 to 2011 was basically stable. The hot spots for the treatment of breast cancer drug were paclitaxel and cisplatin.